The method of treatment of endogenous psychoses
(57) Abstract:The invention relates to medicine, namely to psychiatry. In order to overcome resistance to pharmacotherapy, reduction of terms of treatment and reduce the side effects of pharmacotherapy at the same time introducing neuroleptic drugs extended 4-week action klopicksol depot dose 1200-1600 mg in combination with piportil L 4 at a dose of 400-600 mg or haloperidol - decanoate dose of 400-600 mg intramuscularly 1 time per week. The course of treatment 4-6 injections. The invention relates to medicine, namely to psychiatry, and can be used for the treatment of patients with endogenous psychoses, resistant to pharmacotherapy.There is a method of treatment of endogenous psychoses by conducting combined pharmacotherapy in the form of destination antipsychotic drug prolonged action (ditt depot) in combination with liponexol (In the Journal of Neuropathology and psychiatry. S. S. Korsakov, 1980, T. 80, vol. 8, S. 1211-1216).The disadvantage of this method is the lack of efficiency in 40-70% of cases and the presence of side effects, long duration of treatment (3-6 months).This goal is achieved by the fact that simultaneously administered antipsychotic long-acting drugs (4 - week): Klopicksola depot dose 1200-1600 mg and piportil L 4 at a dose of 400-600 mg or haloperidol decanoate dose of 400-600 mg, intramuscularly 1 time per week: course of treatment 4-6 injections.It was difficult to assume that in the absence of the effect of different types of combination pharmacotherapy, including combinations of multiple antipsychotic drugs of different chemical groups, including the combined use of one of the long-acting drugs, the simultaneous introduction of two antipsychotic long-acting drugs in appropriate doses, 1 every week, with a course of 4-6 weeks will allow you to get a positive therapeutic effect in patients with resistance.This fact, apparently, the difference additional therapeutic mechanism, including effects on the immune structure, which is conrmed by the treatment process, the s-class "A", reduction antiscarring antibodies, circulating immune complexes, antitonicity antibodies on average by 30% compared to initial level).It should also be noted unexpected result no gain side effects with simultaneous introduction 2 long-acting drugs in our proposed doses.The method is as follows.A patient with a prolonged attack of schizophrenia with resistance to different methods adequate differentiated traditional pharmacotherapy after clinicolaboratory survey administered 1 time per week intramuscularly simultaneously two prolonged neuroleptic 4 - week action - Klopicksola depot dose 1200-1600 mg and piportil L 4 or haloperidol decanoate dose of 400-600 mg background corrector trihexyphenidyl 6-12 mg daily, depending on individual tolerability of psychotropic drugs. Weekly monitor and record how the dynamics of mental States ( formalized scales), and the severity of various side effects. Treatment for 4-6 injections of each drug. After cupping psychosis dose neuroleptics prolonged action gradually reduced to Agnes: schizophrenia paroxysmal paranoid, hallucinatory-paranoid syndrome.Mentally ill since 1980, when, after a severe emotional stress began to perceive verbal pseudohallucinations threatening and commenting character, expressed delusions relations, persecution, poisoning. Was hospitalized in a psychiatric hospital, where he remained for 4 months, received traditional treatment with psychotropic drugs - neuroleptics and antidepressants. In the next 6 times was hospitalized due to delusions, auditory hallucinations, inappropriate behaviour. The duration of the last two episodes was 120 and 160 days. Before this hospitalization, the patient's condition deteriorated again appeared auditory hallucinations, delusional ideas, relationships, persecution, poisoning, expressed fear and anxiety, tension and insomnia, significantly decreased mood, behavior has become inadequate, the correction did not respond. Traditional treatment with haloperidol intramuscularly at a dose of 30 mg per day for 20 days and at a dose of 60 mg per day for 30 days was ineffective, despite the addition of 200 mg of amitriptyline, 75 kg of disarcina, 90 mg stelazine.In the absence of those is peridol-decanoate dose of 300 mg intramuscularly 1 time per week. The condition of the patient after 4 injections remained unchanged. Also proved ineffective therapy combination piportila L 4 at a dose of 300 mg intramuscularly 1 time per week and haloperidol in a dose of 90 mg per day for 4 weeks. Side effects were moderate.After the clinical and laboratory examination the patient was assigned to the combination Klopicksola depot at a dose of 1200 mg and piportila L 4 at a dose of 600 mg intramuscularly 1 time per week and concealer trihexyphenidyl 18 mg per day. A week after the first couple of injections in the patient's condition was marked by a clear positive trend: slightly decreased the relevance of delusional experiences, less and less long steel auditory hallucinations, decreased fear and anxiety, tension, improve sleep. Within a week the side effects were insignificant. By the end of the second week after the second pair intramuscular injection Klopicksola depot at a dose of 1200 mg and piportila L 4 at a dose of 600 mg was noted moderate reduction of fear and anxiety, several improved mood, relatively rare steel verbal hallucinations. The patient became more willing to talk about their experiences, it became less closed, fenced off, the dose of 1200 mg and piportila L 4 at a dose of 600 mg, the patient became much calmer and more appropriately, slightly decreased rezonerstvu thinking, become more rare and less severe mood swings disappeared vital shade of depression and separate delusional ideas, others have become less relevant.By the end of the fourth week of therapy almost all psychopathological symptoms, which constitutes the basis of this psychotic attack, underwent a considerable reduction. Disappeared fear and anxiety, tension leveled mood, much less actual steel remaining separate delusional ideas, rarely and for a short period of time there were auditory hallucinations, thought and behavior have become more adequate. I have the desire to watch television, to communicate with a wider range of patients and members of the medical staff.In the subsequent dose Klopicksola depot was reduced to 400 mg 1 time per week, and piportila L 4 to 200 mg, then 1 every 2-3 weeks. In connection with distinct stabilization, the patient was discharged under the supervision of the district psychiatrist, continued outpatient receiving maintenance doses of psychotropic drugs, and over the years, his condition was satisfactory.Thus, to luciopercae attack of schizophrenia in 4 weeks, much less than the previous period 120 and 160 days, side effects were not observed, in contrast to previously held courses of treatment, kurirovavshih traditional methods pharmacotherapy.In this way the treatment of 30 patients with schizophrenia resistant to traditional pharmacotherapy (including as a combination of conventional neuroleptics different chemical groups, or a combination of conventional neuroleptic and neuroleptic prolonged action) in the absence of therapeutic effect within 2-6 months.As a result of applying our proposed method, the positive effect of treatment was observed in 21 patients (70%). Terms of edema was significantly reduced to 4-8 weeks, decreased the severity and frequency of side effects by 30% The method of treatment of endogenous psychoses by conducting combined pharmacotherapy, characterized in that simultaneously administered neuroleptic drugs extended 4-week action: Klopicksola depot dose 1200 1600 mg in combination with piportil L4 at a dose of 400 - 600 mg or haloperidol-decanoate dose of 400 to 600 mg intramuscularly 1 time per week, the course of treatment 4 to 6 injections.
FIELD: organic chemistry, natural compounds, medicine, oncology.
SUBSTANCE: invention represents new saponin mixtures used for inhibition of initiation and activation of mammalian epithelial cell in pre-malignant or malignant state, for stimulation of apoptosis of mammalian malignant cell, prophylaxis of anomalous proliferation of mammalian epithelial cell, for treatment of inflammatory and regulation of angiogenesis in mammal. These mixtures are isolated form plants of species Acacia victoriae. Also, invention relates to methods for their applying. These compounds can comprise triterpene component, such as acacic or oleanolic acid to which oligosaccharides and monoterpenoid components are joined. Mixtures and compounds elicit properties associated with regulation of apoptosis and cytotoxicity of cells and strong anti-tumor effect with respect to different tumor cells.
EFFECT: valuable medicinal properties of compositions.
43 cl, 53 tbl, 50 dwg, 44 ex
FIELD: organic chemistry, chemical technology, medicine, oncology, pharmacy.
SUBSTANCE: invention relates to new derivative of taxane of the formula (I):
that elicits strong antitumor effect. Also, invention relates to intermediates substances, a method for preparing compound of the formula (I), a method for preparing 1,14-β-hydroxy-1,14-carbonate-baccatin III-derivatives substituted with isoserine residue at position 3 and to pharmaceutical composition based on compounds of the formula (I). Invention provides preparing new derivative of taxane that elicits higher activity and reduced toxicity as compared with paclitaxel.
EFFECT: improved preparing method, enhanced and valuable medicinal properties of compound.
10 cl, 7 tbl, 6 ex
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to new derivatives of borrelidin of the general formula (I)
wherein R represents the group of the general formulae -COOR1, -CONR2R3, -CONR4CONR2R5 or -CH2OR6 wherein R1 represents (C2-C6)-alkyl group, (C1-C6)-alkyl group substituted with hydroxyl group or 5-8-membered saturated nitrogen-containing heterocyclic group (it can comprise oxygen atom in addition to nitrogen atom) or 5-6-membered nitrogen-containing aromatic heterocyclic group or (C3-C6)-cycloalkyl group; R2 and R3 are similar or different and represent independently hydrogen atom or (C1-C6)-alkyl group that can be substituted optionally with hydroxyl, (C2-C5)-alkoxycarbonyl or 5-8-membered saturated nitrogen-containing heterocyclic group (it can comprises oxygen atom in addition to nitrogen atom) or 5-6-membered aromatic homocyclic group or aromatic heterocyclic group comprising oxygen and/or nitrogen atom, 5-6-membered cycloalkyl or heteroaryl group; R4 and R5 are similar or different and represent independently hydrogen atom or (C3-C6)-cycloalkyl group; R6 represents hydrogen atom; also, invention relates to tautomers, solvates of these compounds, their mixtures and acid-additive salts. Also, invention relates to pharmaceutical compositions comprising compounds of the general formula (I) as an active component. Angiogenesis inhibitors of the present invention inhibit formation of new vessels in tissues of live organisms and can be used for prophylaxis and inhibition of the angiogenesis process arising in the tumor proliferation, and for prophylaxis of formation of tumor metastasis. Invention provides preparing new derivatives of borrelidin eliciting the value physiological effect.
EFFECT: valuable medicinal properties of compounds.
8 cl, 15 ex
FIELD: medicine, hepatology.
SUBSTANCE: at achieving alkaline phosphatase of 580 U and more one should introduce ursodesoxycholic acid at the dosage of 15-20 mg/kg and orlistate at the dosage of 90-100 mg twice or thrice daily for patients with steatohepatitis. According to normalization of clinical and biochemical values of blood analyses it is possible to conclude upon successfulness of therapy performed. The method provides clinic-laboratory remission of the disease.
EFFECT: higher efficiency of therapy.
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to new acid-additive nitrate salts of compounds taken among salbutamol, cetirizine, loratidine, terfenadine, emedastine, ketotifen, nedocromil, ambroxol, dextrometorphan, dextrorphan, isoniazide, erythromycin and pyrazinamide. Indicated salts can be used for treatment of pathology of respiratory system and elicit an anti-allergic, anti-asthmatic effect and can be used in ophthalmology also. Indicated salts have less adverse effect on cardiovascular and/or gastroenteric systems as compared with their non-salt analogues. Also, invention proposes pharmaceutical compositions for preparing medicinal agents for treatment of pathology of respiratory system and comprising above indicated salts or nitrate salts of metronidazol or aciclovir.
EFFECT: improved and valuable properties of compounds.
6 cl, 5 tbl, 19 ex
FIELD: organic chemistry, medicine, oncology, pharmacy.
SUBSTANCE: invention relates to a new pentacyclic compound derivative of taxane represented by the formula:
wherein R1 represents dimethylaminomethyl group or morpholinomethyl group; R2 represents halogen atom or alkoxy-group comprising from 1 to 6 carbon atoms, or its salt eliciting an antitumor effect, and to a medicine agent based on its. Invention provides preparing new derivatives of taxane eliciting the valuable biological effect.
EFFECT: valuable medicinal properties of compound.
13 cl, 1 dwg, 4 tbl, 16 ex
FIELD: woodworking industry.
SUBSTANCE: invention relates to methods for recovering and purifying native bioflavonoids: dihydroquercitine and dihydrokaempferol from larch wood extracts. Method of recovering bioflavonoids from larch wood extracts is characterized by that freeze-dried extract is dissolved in ethylacetone/water mixture composed in specified proportion, specified amount of resulting solution is introduced into column filled with urea (sorbent) preliminarily equilibrated with ethylacetate, and column is then eluted with an ester and/or ketone having boiling point below 120°C, or with ethylacetate/acetone mixture at specified ratio. Eluate is collected and evaporated until crystallization is observed and then cooled. Separated crystals are rinsed and dried.
EFFECT: enabled single-step process for separating dihydroquercitine and dihydrokaempferol from resinous impurities and other polymeric compounds, reduced process expenses, and reduced environmental impact.
4 cl, 1 dwg
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to new semi-synthetic taxanes of the formula (1):
wherein R and R1 can be similar or different and represent hydrogen atom (H), (C1-C18)-acyl group, benzoyl group; R2 and R3 represent hydrogen atom (H) or R2 and R3 in common form carbonate or thiocarbonate residue; R4 represents benzoyl group optionally substituted at meta-position; R' represents hydrogen atom (H) or (C1-C4)-alkyl; R'' represents (C1-C4)-alkyl or phenyl; R''' represents tert.-butoxy-group under condition that R and R1 both can't represent hydrogen atom (H). Also, invention relates to a pharmaceutical composition based on compounds of the formula (1) eliciting an anti-tumor, anti-angiogenic and anti-arthrosis effect. Invention provides preparing new compounds eliciting cytotoxicity comparable with cytotoxicity of other taxanes but showing reduced systemic toxicity that can be administrated by intravenous and oral routes.
EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions.
6 cl, 1 tbl, 7 ex
FIELD: medicine, therapy, gastroenterology.
SUBSTANCE: method involves preliminary assay of the disorder type in gallbladder motor contraction and bile-excretion ways followed by prescribing thermal low-mineralized hydrocarbonate-sodium-sulfate-calcium-magnesium mineral water in the dose by 200-300 ml, 3 times per a day, 1 h before eating, tubages № 3 with mineral water, bathes and shower with mineral water every day for 10-14 days. In the hypotonic type of motor activity method involves mineral water at temperature 25-30°C, and in the hypertonic type - at temperature 38-40°C. Method provides accelerating in scars formation of ulcers and epithelization of erosions in gastroduodenal system, to prevent frequent exacerbations and to reduce activity of Chelicobacter-induced inflammation.
EFFECT: improved therapy method.
4 tbl, 2 ex
FIELD: organic chemistry, medicine, oncology, pharmacy.
SUBSTANCE: invention relates to new taxanes of the general formula (I)
wherein R2 means benzoyloxy-group; R7 means hydroxyl (OH); R9 means keto-group; R10 means R10aCOO-; R10 means (C2-C6)-alkyl, (C2-C6)-alkenyl, (C3-C6)-cycloalkyl or 5-6-membered heteroaromatic group wherein heteroatom represents oxygen atom (O), sulfur atom (S) or nitrogen atom (N); R14 means hydrogen atom (H); X3 means (C2-C6)-alkyl, (C2-C6)-alkenyl, (C3-C6)-cycloalkyl, phenyl substituted possibly with nitro-group (-NO2), 5-6-membered heteroaromatic group wherein heteroatom represents O, S or N; X5 means -COX10, -COOX10; X10 means (C2-C6)-alkyl, (C2-C6)-alkenyl, (C3-C6)-cycloalkyl, phenyl or 5-6-membered heteroaromatic group wherein heteroatom represents O, S, N; Ac means acetyl. Compounds of the formula (I) elicit antitumor activity.
EFFECT: valuable medicinal properties of compounds.
68 cl, 1 tbl, 6 ex